Matinas BioPharma Establishes Lipid-Based, Anti-Infective Platform, With Acquisition of Aquarius BioTechnologies Inc.
Matinas BioPharma Provides Update on Clinical Development Program for MAT9001 Following FDA Feedback on IND Submission
Matinas BioPharma Appoints Leading Clinical Lipid Specialist and Metabolism Researcher, Kevin C. Maki, Ph.D., to Scientific Advisory Board
Matinas BioPharma Appoints Cardiologist and Lipidology Expert Christie M. Ballantyne, M.D. to Scientific Advisory Board
Matinas BioPharma Receives Authorization From Health Canada to Initiate Human Clinical Study of Lead Product Candidate MAT9001